ArticlePloS one2022

Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin's lymphoma in vitro.

Marion M Malenge et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.